Market News & Trends
Context Therapeutics Announces Encouraging Preclinical Data From Two Programs
Context Therapeutics Inc. recently announced encouraging preclinical data from two pipeline programs, including in vivo combination and immunomodulation data evaluating onapristone extended release (ONA-XR), the company’s…
Enteris BioPharma Highlighted as Game Changer in Special Feature on Innovative Technologies for Improving Drug Solubility & Bioavailability
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq:…
VYNE Therapeutics Announces Positive Phase 1b Efficacy Data From Phase 1b/2a Trial
VYNE Therapeutics Inc. recently announced positive efficacy results from the Phase 1b segment of a Phase 1b/2a clinical trial evaluating FMX114 for the treatment of…
FREEZE-DRYING MICROSCOPY - Unravelling the Complexities of Freeze-Drying Pharmaceuticals With Advanced Microscopy Techniques
Paul Matejtschuk, PhD, Prof Yvonne Perrie, and Robert Gurney, PhD, say FDM is being used to analyze the most challenging formulations that require sophisticated stabilization methods. By altering and adapting the three main freeze-drying stages to specific formulations, researchers are providing the tools needed for the pharma industry to improve its drug development processes and maintain drug stability when scaling up to production.
Catalent Acquires Facility in Oxfordshire to Expand Biologics Capabilities in the UK & Across Europe
Catalent recently announced the acquisition from Vaccine Manufacturing and Innovation Centre UK Limited (VMIC Ltd.) of a biologics development and manufacturing facility currently under….
Rhythm Pharmaceuticals Optimizes Design of EMANATE & DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity
Rhythm Pharmaceuticals, Inc. recently announced modifications intended to optimize its Phase 3 EMANATE and ongoing Phase 2 DAYBREAK trials to focus on rare patient populations,…
Arcutis Completes Enrollment in ARRECTOR Pivotal Phase 3 Trial of Topical Roflumilast Foam in Scalp & Body Psoriasis
Arcutis Biotherapeutics, Inc. recently announced the enrollment of the last subject in its ARRECTOR pivotal Phase 3 trial of topical roflumilast foam in adolescents and…
Medidata & Celsion Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial
Celsion Corporation and Medidata recently announced they presented their findings on the use of a Synthetic Control Arm (SCA) in a completed Phase Ib dose-escalating study of GEN-1 in the neoadjuvant treatment of….
Nurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of Drug-Enhanced Cell Therapy for the Treatment of Patients With Solid Tumors
Nurix Therapeutics, Inc. recently announced the first patient has been dosed in its Phase 1 clinical trial of DeTIL-0255, a drug-enhanced tumor infiltrating lymphocyte therapy and….
Sterling Pharma Solutions Expands Capabilities & Laboratory Capacity
Sterling Pharma Solution recently announced a £1 million expansion project at its Deeside, UK site, which is the company’s dedicated bioconjugation and antibody-drug conjugates (ADCs)…
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Potential First-in-Class Oncolytic Peptide-Based Immunotherapy
Verrica Pharmaceuticals Inc. recently announced the first patient has been dosed in the company’s Phase 2 trial of LTX-315, a potential first-in-class oncolytic peptide, for the….
Processa Pharmaceuticals Announces First Patient Enrolled in Phase 2A Trial for the Treatment of Gastroparesis
Processa Pharmaceuticals, Inc. recently announced it has enrolled its first patient in the Phase 2A clinical trial of PCS12852 in patients with moderate-to-severe gastroparesis. Gastroparesis…
Agenus’ CD137 Agonist Advances in the Clinic, Triggering Milestone Payment From Gilead
Agenus Inc. recently announced receipt of a $5-million clinical milestone payment for AGEN2373 (conditionally active CD137 agonist). AGEN2373 is being evaluated in a Phase 1b…
UK Government to Support Expansion of Croda’s Lipid Systems Manufacturing Facility
Croda International Plc that uses smart science to create high performance ingredients and solutions that improve lives, recently announced that it has been awarded a £15.9 million grant by the UK Government to expand….
New BD Assay Advances Immunology Research Capabilities in the Developing Field of Multiomics
BD (Becton, Dickinson and Company) recently released the BD Rhapsody TCR/BCR Multiomic Assay, an innovative set of reagents that enables researchers to more easily and…
Proveris Expands Product Portfolio With New Kinaero Cx pMDI Collection System for Delivered Dose Uniformity & Aerodynamic Particle Size Distribution Testing
Proveris Scientific Corporation recently introduced the Kinaero Cx pMDI Collection System to automate the pMDI shaking, priming, dose sample collection, and fire-down for….
Athira Pharma Doses First Subject in Phase 1 Clinical Trial of HGF/MET Positive Modulator
Athira Pharma, Inc. recently announced that the first subject has been dosed in a Phase 1 clinical trial investigating ATH-1020, an orally available,….
Starton Therapeutics Announces FDA Clearance of IND Application
Starton Therapeutics Inc. recently announced the US FDA has cleared an investigational new drug (IND) application for STAR-OLZ in Chemotherapy Induced Nausea and Vomiting (CINV). STAR-OLZ is a multi-day transdermal….
Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial
Inozyme Pharma, Inc. recently announced positive preliminary biomarker, safety, and pharmacokinetic (PK) data from the first three patients treated in the Phase 1 portion of its…
CymaBay Therapeutics Announces Results From 52-Week, Open-Label, Phase 2 Study
CymaBay Therapeutics, Inc. recently announced that results from the Phase 2, 52-week study of seladelpar in patients with primary biliary cholangitis (PBC) have been published…
